Oncolytics Biotech Inc (ONCY)

Jan 08, 2026

Is Oncolytics Biotech Inc. stock a contrarian buyInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Is Oncolytics Biotech Inc. stock a buy for dividend growth - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times

Jan 08, 2026

Jan 08, 2026

Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings - MarketScreener

Jan 08, 2026

Jan 08, 2026

Why Oncolytics Biotech Inc. stock is rated strong buy2025 Valuation Update & Daily Profit Maximizing Trade Tips - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044 - TipRanks

Jan 08, 2026

Jan 08, 2026

Oncolytics Biotech files patent application to extend pelareorep protection By Investing.com - Investing.com India

Jan 08, 2026

Jan 08, 2026

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - Business Wire

Jan 08, 2026

Jan 07, 2026

How $594B in Precision Tech is Cracking the Metastatic Cancer Code - Investing News Network

Jan 07, 2026

Jan 07, 2026

Stocks in play: Oncolytics Biotech Inc - Barchart.com

Jan 07, 2026

Jan 07, 2026

Oncolytics Biotech expands GI cancer advisory board with three experts By Investing.com - Investing.com Nigeria

Jan 07, 2026

Jan 07, 2026

Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials - TipRanks

Jan 07, 2026

Jan 07, 2026

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire

Jan 07, 2026

Dec 31, 2025

Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail

Dec 31, 2025

Dec 31, 2025

What drives Oncolytics Biotech Inc stock priceStock Rotation Strategies & Big Profit Small Investment - earlytimes.in

Dec 31, 2025

Dec 27, 2025

Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 27, 2025

Dec 24, 2025

Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1.5%Here's Why - MarketBeat

Dec 24, 2025

Dec 23, 2025

Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting - ACCESS Newswire

Dec 23, 2025

Dec 20, 2025

Revenue per share of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView — Track All Markets

Dec 20, 2025

Dec 20, 2025

What hedge fund activity signals for Oncolytics Biotech Inc. stockWeekly Profit Recap & Technical Pattern Based Signals - Улправда

Dec 20, 2025

Dec 20, 2025

Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - Улправда

Dec 20, 2025

Dec 19, 2025

Published on: 2025-12-20 04:27:06 - Улправда

Dec 19, 2025

Dec 19, 2025

Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber

Dec 19, 2025

Dec 18, 2025

What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - Улправда

Dec 18, 2025

Dec 18, 2025

Published on: 2025-12-18 16:49:38 - Улправда

Dec 18, 2025

Dec 18, 2025

Lake Street Remains a Buy on Oncolytics Biotech (ONCY) - The Globe and Mail

Dec 18, 2025

Dec 17, 2025

[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan

Dec 17, 2025

Dec 17, 2025

Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter

Dec 17, 2025

Dec 17, 2025

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace

Dec 17, 2025

Dec 16, 2025

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter

Dec 16, 2025

Dec 16, 2025

Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com

Dec 16, 2025

Dec 16, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire

Dec 16, 2025

Dec 16, 2025

Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha

Dec 16, 2025

Dec 16, 2025

Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India

Dec 16, 2025

Dec 16, 2025

Oncolytics Biotech says data backs pelareorep in KRAS-mutant mCRC - marketscreener.com

Dec 16, 2025

Dec 16, 2025

Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer - TipRanks

Dec 16, 2025

Dec 16, 2025

Oncolytics reports 33% response rate in hard-to-treat colorectal cancer By Investing.com - Investing.com South Africa

Dec 16, 2025

Dec 15, 2025

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis - GlobeNewswire Inc.

Dec 15, 2025

Dec 15, 2025

United States Oncolytic Virus Therapy Market to Reach USD 199.98 - openPR.com

Dec 15, 2025

Dec 12, 2025

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Cantech Letter

Dec 12, 2025

Dec 12, 2025

Platform Oncology Technologies Drive Multi-Indication Treatment Expansion - The Globe and Mail

Dec 12, 2025

Dec 12, 2025

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times

Dec 12, 2025